Close Menu

influenza

Gen-Probe said the assay is the only FDA-cleared molecular diagnostic test that can simultaneously detect seasonal A/H1, seasonal A/H3, and 2009 H1N1.

A number of molecular diagnostic tests that were cleared for emergency use during the 2009 H1N1 influenza pandemic will have to seek full FDA clearance now that HHS has declared the emergency over.

The antibody profile could potentially be used to improve stratification of patient cohorts in clinical trials or as a point-of-care test to determine whether a patient needs vaccination, Reinhard Hiller, managing director of CPGR, told ProteoMonitor.

Doing so, however, will require the company to secure additional funding, and it is currently evaluating its options, a company official said.

CPGR will be developing multiplex protein array-based antibody profiling assays and related bioinformatic analysis methods for the project with the ultimate aim of creating a biomarker signature that can be used for companion diagnostic purposes.

Through their phylogenetic analysis of influenza A strains circulating in pigs at a Hong Kong slaughterhouse, researchers have detected viral reassortment involving the H1N1 "swine flu" virus.

The partners aim to identify biomarkers that may predict how patients react to seasonal influenza vaccinations.

"The discovery of svRNAs that play a critical role in flu virus replication opens the door for the development of novel RNA therapeutics for the treatment of flu infection, an area of major unmet need," according to an Alnylam official.

Simplexa, manufactured by Quest's Focus Diagnostics business, is the first test to be cleared by the FDA to aid in detecting and differentiating influenza A and 2008 H1N1 influenza viral RNA.

As a result of the 510(k) clearance, Quest's Simplexa Influenza A H1N1 test will be the only one that can be marketed after June 23 when the public emergency stemming from the virus is lifted.

Pages

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.